Gallbladder Cancer - Pipeline Insight, 2024

This “Gallbladder cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Gallbladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Gallbladder cancer Understanding

Gallbladder cancer: Overview

Gallbladder cancer is a small, pear shaped organ located beneath the liver. The bladder stores bile enzymes produced by the liver and helps in digestion. Gallbladder cancer is a rare type of cancer that is characterized by the abnormal growth of cells in the Gallbladder cancer area. Most of the Gallbladder cancer begins in glandular cells which form the lining of the inner surface of the organ. This type of cancer is very rare and is caused due to the DNA mutations in the Gallbladder cancer cells. Gallbladder cancer is more common in middle aged women with a history of gallstones. However, it can also occur in men. Gallbladder cancer can be of various types such as papillary adenocarcinomas, adenosquamous carcinoma, squamous cell carcinoma, and others.

Gallbladder cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gallbladder cancer pipeline landscape is provided which includes the disease overview and Gallbladder cancer treatment guidelines. The assessment part of the report embraces, in depth Gallbladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gallbladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Gallbladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Gallbladder cancer.

Gallbladder cancer Emerging Drugs Chapters

This segment of the Gallbladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gallbladder cancer Emerging Drugs

Durvalumab: CelgneCelgene’ new drug candidate, Durvalumab, is human immunoglobulin G1 kappa monoclonal antibody that is in development for the treatment of Gallbladder cancers. It inhibits the immune response by blocking the interaction of PD-L1 with PD 1 and CD80. The drug has demonstrated good efficacy and safety results in its phase I clinical trials.

ONC 201: Ohara PharmaceuticalsOhara Pharmaceutical’s “breakthrough” drug ONC 201 is a small orally administered molecule in development for the treatment of Gallbladder cancer. The drug inactivates the Akt/ERK signaling, leading to upregulation of the proapoptotic immune cytokine TRAIL.

Gallbladder cancer: Therapeutic Assessment

This segment of the report provides insights about the different Gallbladder cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gallbladder cancer

There are approx. 10+ key companies which are developing the therapies for Gallbladder cancer. The companies which have their Gallbladder cancer drug candidates in the most advanced stage, i.e. phase II include, Celgene.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Gallbladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intramuscular
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gallbladder cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gallbladder cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gallbladder cancer drugs.

Gallbladder cancer Report Insights

• Gallbladder cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Gallbladder cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gallbladder cancer drugs?
• How many Gallbladder cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gallbladder cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gallbladder cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gallbladder cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Celgene
• MedImmune
• Ohara Pharmaceuticals

Key Products

• Durvalumab
• Tremelimumab
• ONC 201

This product will be delivered within 2 business days.